Equities Research Analysts’ Downgrades for February 10th (AMPS, ATKR, CGBD, COP, ILMN, KHC, MLCO, MRK, NTAP, PLRX)

Equities Research Analysts’ downgrades for Monday, February 10th:

Altus Power (NYSE:AMPS) was downgraded by analysts at UBS Group AG from a buy rating to a neutral rating. The firm currently has $5.00 target price on the stock.

Atkore (NYSE:ATKR) was downgraded by analysts at Loop Capital from a buy rating to a hold rating. Loop Capital currently has $65.00 price target on the stock, down from their previous price target of $115.00.

Carlyle Secured Lending (NASDAQ:CGBD) was downgraded by analysts at Bank of America Co. from a buy rating to an underperform rating. They currently have $17.00 price target on the stock.

ConocoPhillips (NYSE:COP) was downgraded by analysts at Raymond James from a strong-buy rating to an outperform rating. The firm currently has $124.00 target price on the stock, down from their previous target price of $157.00.

Illumina (NASDAQ:ILMN) was downgraded by analysts at Barclays PLC from an equal weight rating to an underweight rating. The firm currently has $100.00 price target on the stock, down from their previous price target of $130.00.

Kraft Heinz (NASDAQ:KHC) was downgraded by analysts at Mizuho from an outperform rating to a neutral rating. The firm currently has $31.00 target price on the stock, down from their previous target price of $38.00.

Melco Resorts & Entertainment (NASDAQ:MLCO) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating. Citigroup Inc. currently has $6.00 target price on the stock, down from their previous target price of $10.00.

Merck & Co., Inc. (NYSE:MRK) was downgraded by analysts at TD Cowen from a buy rating to a hold rating. The firm currently has $100.00 price target on the stock, down from their previous price target of $121.00.

NetApp (NASDAQ:NTAP) was downgraded by analysts at Susquehanna from a positive rating to a neutral rating. The firm currently has $130.00 target price on the stock, down from their previous target price of $155.00.

Pliant Therapeutics (NASDAQ:PLRX) was downgraded by analysts at HC Wainwright from a buy rating to a neutral rating.

Pliant Therapeutics (NASDAQ:PLRX) was downgraded by analysts at Royal Bank of Canada from an outperform rating to a sector perform rating. The firm currently has $4.00 price target on the stock, down from their previous price target of $45.00.

Pliant Therapeutics (NASDAQ:PLRX) was downgraded by analysts at Wells Fargo & Company from an overweight rating to an equal weight rating. Wells Fargo & Company currently has $4.00 price target on the stock, down from their previous price target of $41.00.

Pliant Therapeutics (NASDAQ:PLRX) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating. They currently have $4.00 price target on the stock, down from their previous price target of $40.00.

Pliant Therapeutics (NASDAQ:PLRX) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating.

Skyworks Solutions (NASDAQ:SWKS) was downgraded by analysts at Argus from a buy rating to a hold rating.

Triumph Group (NYSE:TGI) was downgraded by analysts at Wolfe Research from an outperform rating to a peer perform rating.